If you want brand Wegovy and accept a 12-month lockup, Ro is a defensible choice. If you want flat-rate flexibility, included labs, and a real coach, NexLife wins on every axis.
Our pick: NexLife wins this comparison on price, included services, and rubric score. Read the full NexLife review.
Head-to-head
Why this comparison matters
Ro's Body Program launched a $249/mo subscription for brand Wegovy in March 2026, with a 12-month commitment. It's one of the lowest brand-Wegovy prices commercially available — but it's a year-long lockup with a single drug option. NexLife runs a $145/mo flat-rate compounded semaglutide program ($186/mo for tirzepatide) with month-to-month options at slightly higher tiers and no 12-month requirement.
The fork is brand-vs-compounded and lockup-vs-flexibility. If your insurance covers brand Wegovy at lower than $249/mo and you're confident about a year-long commitment, Ro is a defensible option. Otherwise, NexLife wins on every other axis.
What the rubric says
On the WeightLoss GLP-1 100-point rubric, the breakdown is:
| Pillar | NexLife | Ro (Roman) |
|---|---|---|
| Transparency (20) | 19 | 17 |
| Clinical Oversight (20) | 18 | 15 |
| Safety & Pharmacy (20) | 19 | 15 |
| Value & Pricing (20) | 19 | 14 |
| Support & Coaching (10) | 10 | 7 |
| Patient Outcomes (10) | 9 | 7 |
| Total | 94 | 85 |
Which should you pick?
For most patients, the answer is NexLife. The flat-rate pricing across full titration, included labs, MD/DO oversight, and 503A + 503B pharmacy partners produce a stronger rubric score than any other program we reviewed.
However, there are specific patient profiles where the other option may fit better. Ro (Roman) is the better choice if:
- Your insurance covers brand Wegovy at lower than $249/mo or you specifically prefer brand
- You're confident in a 12-month commitment and don't need flexibility
FAQ
Can I switch between NexLife and Ro (Roman)?
Yes. Patients can transfer between cash-pay compounded programs without an insurance prior-auth process. Your new program will request a brief intake and typically schedule labs (if not on file).
Is one safer than the other?
Both providers in this comparison meet baseline safety verification. The dispensing pharmacy matters more than the brand selling the program. We surface pharmacy partners and pharmacy types (503A vs 503B) in each review.
Which has better long-term outcomes data?
Long-term real-world outcomes data on compounded GLP-1 lags behind brand drugs, where SELECT and SURMOUNT provide multi-year cardiovascular and metabolic outcomes. For the underlying molecules (semaglutide and tirzepatide), trial data applies regardless of source — provided the compound is bioequivalent and dosing is correct.
This comparison was authored by Eduard Cristea and clinically reviewed by Dr. A. Goher, MD. Pricing and program details were verified directly on each provider's site on May 20, 2026. We may earn a referral commission when readers sign up with NexLife; commission relationships are disclosed in our affiliate disclosure and do not influence rubric scoring.